TRACLEER Drug Patent Profile

When do Tracleer patents expire, and when can generic versions of Tracleer launch?

Tracleer is a drug marketed by Actelion and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-eight patent family members in twenty-three countries.

The generic ingredient in TRACLEER is bosentan. There are nineteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bosentan profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tracleer

A generic version of TRACLEER was approved as bosentan by SUN PHARM on April 26^th, 2019.

Summary for TRACLEER

International Patents:	28
US Patents:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	44
Patent Applications:	5,801
Drug Prices:	Drug price information for TRACLEER
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRACLEER
What excipients (inactive ingredients) are in TRACLEER?	TRACLEER excipients list
DailyMed Link:	TRACLEER at DailyMed

See drug prices for TRACLEER

Recent Clinical Trials for TRACLEER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Humanis Saglık Anonim Sirketi	PHASE1
City of Hope Medical Center	Phase 1
National Cancer Institute (NCI)	Phase 1

See all TRACLEER clinical trials

Pharmacology for TRACLEER

Drug Class	Endothelin Receptor Antagonist
Mechanism of Action	Cytochrome P450 2C9 Inducers Cytochrome P450 3A Inducers Endothelin Receptor Antagonists

Paragraph IV (Patent) Challenges for TRACLEER

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRACLEER	for Oral Suspension	bosentan	32 mg	209279	1	2019-02-08

US Patents and Regulatory Information for TRACLEER

TRACLEER is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actelion	TRACLEER	bosentan	TABLET, FOR SUSPENSION;ORAL	209279-001	Sep 5, 2017	AB	RX	Yes	Yes			Y
Actelion	TRACLEER	bosentan	TABLET;ORAL	021290-002	Nov 20, 2001	AB	RX	Yes	Yes
Actelion	TRACLEER	bosentan	TABLET, FOR SUSPENSION;ORAL	209279-001	Sep 5, 2017	AB	RX	Yes	Yes			Y
Actelion	TRACLEER	bosentan	TABLET;ORAL	021290-001	Nov 20, 2001	AB	RX	Yes	No

Expired US Patents for TRACLEER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Actelion	TRACLEER	bosentan	TABLET;ORAL	021290-001	Nov 20, 2001
Actelion	TRACLEER	bosentan	TABLET;ORAL	021290-002	Nov 20, 2001

EU/EMA Drug Approvals for TRACLEER

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International N.V.	Tracleer	bosentan	EMEA/H/C/000401Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III.Efficacy has been shown in:, , , Primary (idiopathic and familial) PAH;, PAH secondary to scleroderma without significant interstitial pulmonary disease;, PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology., , , Some improvements have also been shown in patients with PAH WHO functional class II., , Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.,	Authorised	no	no	no	2002-05-14

International Patents for TRACLEER

When does loss-of-exclusivity occur for TRACLEER?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRACLEER around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20080014002	DISPERSIBLE TABLET
Israel	102138	Sulphonamides their preparation and intermediates therefor and pharmaceutical compositions containing the sulphonamides
Hungary	221203	NEW PYRIMIDINYL SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, PROCESS FOR PRODUCING THEM AND THEIR INTERMEDIATES
Iceland	3877
Greece	3035162
Mexico	9202747	NUEVAS SULFONAMIDAS Y PROCEDIMIENTOS PARA SU PREPARACION.
Hong Kong	1120212	DISPERSIBLE BOSERTAN TABLET

Supplementary Protection Certificates for TRACLEER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0526708	CA 2002 00026	Denmark
0526708	C300097	Netherlands		PRODUCT NAME: BOSENTAN, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN HYDRAAT OF IN DE VORM VAN EEN ESTER VAN DE HYDROXYLGROEP VAN DE 2-HYDROXYETHOXY REST MET EEN ZUUR MET DE FORMULE R5-OH, WAARIN R5 EEN C1-7-ALKANOYL, BENZOYL, OF HETEROCYCLYCARBONYL VOORSTELT; NATL. REGISTRATION NO/DATE: U/1/02/220/001 - 005 20020515; FIRST REGISTRATION: CH IKS 58841 01 - 02 20020228
0526708	02C0042	France		PRODUCT NAME: BOSENTAN MONOHYDRATE; NAT. REGISTRATION NO/DATE: EU/1/02/220/001 20020515; FIRST REGISTRATION: LI - 55841 20020228
0526708	0290017-3	Sweden		PRODUCT NAME: BOSENTAN ELLER ETT SALT DAERAV; NAT. REGISTZRATION NO/DATE: EU/1/02/220/001 20020515; FIRST REGISTRATION: CH 55841 01 20020228
0526708	SPC/GB02/030	United Kingdom		PRODUCT NAME: BOSENTAN 4-(1,1-DIMETHYLETHYL)-N-(6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2(PYRIMIDIN-2-YL)PYRIMIDIN-4-YL)BENZENESULFONAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
0526708	300097	Netherlands

TRACLEER (Bosentan) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Tracleer (bosentan) is a dual endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). This analysis examines its market position, patent landscape, and financial performance, providing insights for strategic R&D and investment decisions.

What is Tracleer's Market Position in Pulmonary Arterial Hypertension?

Tracleer was a first-in-class therapy for PAH, establishing a significant market presence upon its launch. Its mechanism of action targets the endothelin pathway, a key mediator of vasoconstriction and cellular proliferation in the pulmonary arteries. This novel approach provided a critical therapeutic option for patients with a severe and progressive disease.

Therapeutic Landscape Evolution

The PAH treatment landscape has evolved significantly since Tracleer's introduction. Initially, treatment options were limited, positioning Tracleer as a leading therapy. Over time, new drug classes and improved understanding of PAH pathophysiology have introduced a range of alternative and complementary treatments. These include prostacyclin analogs, phosphodiesterase type 5 (PDE5) inhibitors, and newer endothelin receptor antagonists (ERAs) with potentially improved safety or efficacy profiles.

• Early Market Dominance: Tracleer held a dominant position for many years, benefiting from its first-mover advantage and robust clinical trial data demonstrating improved exercise capacity and reduced clinical worsening in PAH patients.
• Competitive Entry: The market has since seen the introduction of several other ERAs, such as ambrisentan (Letairis) and macitentan (Opsumit). These agents compete directly with Tracleer and offer different pharmacokinetic and pharmacodynamic profiles, as well as varying safety considerations.
• Combination Therapies: The understanding that PAH is a multifactorial disease has led to the development and adoption of combination therapies. Tracleer is often used as part of a multi-drug regimen, particularly in patients with more severe disease or those who have not responded adequately to monotherapy.

Patient Population and Disease Severity

Tracleer is indicated for patients with WHO Group 1 PAH. The disease affects a relatively small but critically ill patient population. The severity of PAH dictates treatment intensity, with Tracleer being considered for various stages of the disease, often after initial management or for patients requiring more aggressive therapy.

• Disease Prevalence: Pulmonary arterial hypertension is a rare disease. Precise global prevalence figures vary, but estimates suggest a prevalence of approximately 15-60 cases per million people worldwide [1].
• Treatment Guidelines: International treatment guidelines, such as those from the European Society of Cardiology and the American Heart Association, have historically included Tracleer in their recommendations for PAH management. These guidelines are periodically updated to reflect new scientific evidence and emerging therapies.

Regulatory Approvals and Geographic Reach

Tracleer received its initial approval from the U.S. Food and Drug Administration (FDA) in November 2001 and from the European Medicines Agency (EMA) in July 2001. It has since gained approval in numerous other countries, establishing a global presence.

• FDA Approval Date: November 21, 2001
• EMA Approval Date: July 20, 2001
• Key Markets: United States, European Union, Japan, Canada, Australia.

What is the Patent and Exclusivity Landscape for Tracleer?

The patent and market exclusivity landscape has been a critical factor in Tracleer's financial trajectory. The expiration of key patents has led to generic competition, significantly impacting its market share and pricing.

Core Patents and Expiration

The primary patents protecting Tracleer covered its chemical composition, methods of use, and manufacturing processes. The expiration of these patents has opened the door for generic manufacturers.

• Key Composition of Matter Patents: The original patents covering bosentan's chemical structure have long since expired. For instance, U.S. Patent No. 5,206,254, related to endothelin antagonists, including bosentan, expired in November 2012 [2].
• Method of Use Patents: Additional patents covering specific methods of treating PAH with bosentan also expired. These often provided secondary protection, extending market exclusivity for a period.
• Pediatric Exclusivity: In the U.S., Tracleer was granted 6 months of additional pediatric exclusivity, which expired in May 2013, providing a limited extension of market protection beyond the primary patent expiry.

Generic Entry and Market Impact

The loss of patent protection allowed for the introduction of generic versions of bosentan, leading to a rapid decline in Tracleer's market share and revenue.

• First Generic Entrants: Generic versions of bosentan began appearing in major markets following patent expiries. For example, generic bosentan became available in the U.S. around 2013.
• Price Erosion: Generic competition typically leads to substantial price reductions. The average selling price of bosentan has decreased significantly post-patent expiry due to the increased number of suppliers and competitive pricing strategies.
• Market Share Shift: Brand-name Tracleer's market share has been largely replaced by generic bosentan products. Pharmaceutical companies that previously marketed Tracleer now often focus on newer, still-patented therapies.

Intellectual Property Litigation

Throughout Tracleer's lifecycle, there have been instances of intellectual property litigation, primarily concerning patent validity, infringement, and challenges to regulatory exclusivities. These legal battles are common for blockbuster drugs and can influence the timing and nature of generic entry.

What has been Tracleer's Financial Trajectory?

Tracleer achieved significant commercial success during its period of market exclusivity, generating substantial revenue for its original developer. However, its financial trajectory has been sharply altered by the advent of generic competition.

Peak Sales and Revenue Generation

Tracleer was a blockbuster drug for Actelion, its developer, reaching peak annual sales in the hundreds of millions of dollars.

• Peak Sales Year: Tracleer achieved peak annual sales in the range of approximately $1.4 billion to $1.5 billion in the years leading up to significant patent expirations.
• Cumulative Revenue: Over its patent-protected lifespan, Tracleer generated billions of dollars in cumulative revenue, reflecting its importance in PAH treatment and its market penetration.
• Actelion's Portfolio: For many years, Tracleer was a cornerstone of Actelion's revenue, forming the financial backbone of the company and funding its subsequent R&D efforts.

Post-Patent Expiration Revenue Decline

Following the entry of generic bosentan, Tracleer's revenue experienced a dramatic decline.

• Sales Decline Rate: Post-patent expiry, sales of branded Tracleer declined by over 80-90% within a few years as market share shifted to generics.
• Generic Market Value: While branded Tracleer sales plummeted, the overall market for bosentan (including generics) continued, albeit at a significantly lower price point. The total market value for bosentan products is now a fraction of its peak branded sales.
• Actelion's Strategic Shift: The decline in Tracleer revenue prompted Actelion to diversify its pipeline and portfolio, eventually leading to its acquisition by Johnson & Johnson in 2017 for approximately $30 billion, partly driven by its newer PAH therapies like Opsumit (macitentan) [3].

Pricing Dynamics

The pricing of Tracleer has been subject to considerable pressure. Initially, as a novel, life-saving therapy with no direct competitors, it commanded a premium price. Post-patent expiry, this pricing dynamic reversed entirely.

• Branded Pricing: Before generic entry, Tracleer's annual cost could range from $50,000 to over $100,000 per patient, depending on dosage and geographic market.
• Generic Pricing: Generic bosentan is available at a fraction of the branded price, often at 10-20% of the original cost, making it more accessible but drastically reducing overall market revenue for the active pharmaceutical ingredient.
• Payer Negotiations: Payers, including insurance companies and national health systems, actively negotiate pricing and formulary placement, especially after generic entry, to manage healthcare expenditures.

What are the Future Market Considerations for Tracleer and its Generics?

The market for bosentan is now largely dominated by generic competition. Future considerations will revolve around the entrenched position of generics, potential niche applications, and the evolving PAH treatment paradigm.

Generic Market Share and Competition

Generic bosentan is the primary product in the market for this drug. Competition among generic manufacturers will continue to drive pricing down.

• Multiple Generic Manufacturers: Several pharmaceutical companies produce generic versions of bosentan, leading to a fragmented and highly competitive generic market.
• Availability and Accessibility: Generic availability has increased patient access to bosentan therapy, particularly in markets where cost was a significant barrier.
• Quality and Bioequivalence: Regulatory bodies ensure generic products are bioequivalent to the branded drug, maintaining therapeutic equivalence.

Evolving PAH Treatment Landscape

The PAH treatment landscape continues to evolve with new therapeutic targets and drug development. This will influence the long-term demand for all PAH medications, including bosentan.

• Newer Therapies: Advanced therapies and novel drug candidates are continuously being developed for PAH, potentially offering improved efficacy or better safety profiles.
• Personalized Medicine: The move towards personalized medicine in PAH may lead to more targeted treatment approaches, potentially impacting the broad use of older therapies.
• Combination Therapy Dominance: The trend towards combination therapy is likely to continue, with bosentan (in its generic form) being one component in complex treatment regimens.

Remnant Branded Market (Limited)

While most of the market has transitioned to generics, there may be a small remnant of the branded Tracleer market, potentially driven by physician preference, patient loyalty, or specific payer contracts that maintain some branded usage. However, this segment is expected to be negligible.

Key Takeaways

• Tracleer (bosentan) was a groundbreaking first-in-class therapy for pulmonary arterial hypertension (PAH), establishing significant market dominance.
• The expiration of key patents, particularly composition of matter patents around 2012-2013 in major markets, led to the rapid entry of generic bosentan.
• Generic competition caused a dramatic decline in branded Tracleer revenue, transforming its financial trajectory from a blockbuster to a niche product for its original developer.
• Actelion, the original developer, successfully transitioned its PAH franchise with newer, still-patented therapies like macitentan (Opsumit), leading to its acquisition by Johnson & Johnson.
• The current market for bosentan is almost entirely composed of generic products, characterized by intense price competition and increased patient accessibility.
• The evolving PAH treatment landscape, with new drug classes and combination therapies, will continue to shape the market dynamics for all PAH medications, including generic bosentan.

Frequently Asked Questions

What is the primary indication for Tracleer (bosentan)?

Tracleer is indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with WHO Group 1 PAH.

When did Tracleer's primary patents expire in major markets like the U.S.?

Key patents for Tracleer began expiring around 2012-2013 in markets like the United States, allowing for generic entry.

Who originally developed Tracleer?

Tracleer was originally developed by Actelion.

Has Johnson & Johnson acquired the company that developed Tracleer?

Yes, Johnson & Johnson acquired Actelion in 2017.

What is the current market status of Tracleer?

The market for bosentan is now dominated by generic versions, with branded Tracleer having a negligible market share.